COPENHAGEN, Denmark, Aug. 11, 2014 /PRNewswire/ -- Forward Pharma A/S, a biopharmaceutical company focused on a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis, today announced that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the offering have not yet been determined. Forward Pharma intends to list its ordinary shares on the NASDAQ under the ticker symbol "FWP."
Leerink Partners LLC is acting as sole book running manager and as a representative of the underwriters for the proposed offering. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus related to the offering may be obtained from: Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110 or by email at [email protected], or by calling (800) 808-7525.
A registration statement relating to Forward Pharma's securities has been filed with the United States Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Andy Brimmer / Dan Katcher / Jennifer Beugelmans
Joele Frank, Wilkinson Brimmer Katcher
SOURCE Forward Pharma A/S